eXoZymes, Inc. (EXOZ)
NASDAQ: EXOZ · Real-Time Price · USD
10.33
-0.28 (-2.59%)
At close: Apr 28, 2026, 4:00 PM EDT
10.13
-0.19 (-1.89%)
After-hours: Apr 28, 2026, 4:00 PM EDT
Company Description
eXoZymes, Inc. operates as a development stage biotechnology company.
The company focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing.
The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025.
eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
eXoZymes, Inc.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Michael Heltzen |
Contact Details
Address: 750 Royal Oaks Drive, Suite 106 Monrovia, California 91016 United States | |
| Phone | 626 415 1488 |
| Website | exozymes.com |
Stock Details
| Ticker Symbol | EXOZ |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002010788 |
| CUSIP Number | 461874109 |
| ISIN Number | US4618741098 |
| Employer ID | 83-4550057 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Michael Heltzen | President and Chief Executive Officer |
| Dr. Tyler Korman Ph.D. | Co-Founder and Chief Scientific Officer |
| Dr. Paul Opgenorth Ph.D. | Co-Founder and Vice President of Development |
| James U. Bowie Ph.D. | Founder and Independent Director |
| Fouad Nawaz | Vice President of Finance |
| Damien A. Perriman | Chief Commercial Officer |
| Lasse H. Gorlitz | Vice President of Communications |
| Michael Burns | Executive Vice President of Energy Transition |
| Amy Lunzer | Chief of Staff |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2026 | 8-K | Current Report |
| Apr 9, 2026 | 424B5 | Filing |
| Mar 31, 2026 | 8-K | Current Report |
| Mar 30, 2026 | 10-K | Annual Report |
| Feb 5, 2026 | 8-K | Current Report |
| Jan 26, 2026 | 424B2 | Prospectus |
| Jan 23, 2026 | EFFECT | Notice of Effectiveness |
| Jan 16, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Dec 16, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Dec 15, 2025 | DRS | [Cover] Draft Registration Statement |